Key facts
as of Sep 2026- Neurona Therapeutics’s last known valuation is $1.1B (Apr 2026).
- It has raised $347.6M across 6 recorded rounds; the latest was Later Stage VC (Series F) ($101.7M) in Mar 2025.
- Notable investors include Fidelity Management & Research Company, Viking Global Investors, National Institutes of Health, University of California, Alexandria Venture Investments — 30 tracked in total.
- 2 institutional filers report fund marks on Neurona Therapeutics across 20 filings.
- Neurona Therapeutics has filed 8 Form Ds with the SEC since 2014, most recently Apr 2025 ($101.7M sold to 46 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 30 names
- ·Watchlist + deal alerts for Neurona Therapeutics
Recorded secondary trades
No secondary trades in Neurona Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
2 filers · latest May 20262 SEC-registered funds reported 20 fair-value marks on Neurona Therapeutics between Apr 2025 and May 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
6 roundsAbout Neurona Therapeutics
Developer of regenerative cell therapies designed for the treatment of chronic neurological disorders. The company provides allogeneic, off-the-shelf neural cell therapies that integrate into neural circuits, replace affected cells, and rebalance electrical activity, enabling medical practitioners to offer patients with chronic neurological conditions long-lasting disease amelioration from a single, one-time dose.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2008
- Employees
- 105
- Website
- neuronatherapeutics.com/
- Ownership
- Privately Held (backing)